
%0 Journal Article
%A Hurt, Aeron C 
%T Antiviral drug resistance in seasonal and pandemic influenza
%J Microbiology Australia
%D 2011/03/01
%V 32
%N 1
%P 26-28
%K 
%R https://doi.org/10.1071/MA11026
%U https://www.publish.csiro.au/paper/MA11026 
%X Two classes of anti-influenza drugs are currently available for the treatment or prophylaxis of influenza. These are the adamantanes (amantadine and rimantadine), which block the activity of the M2 ion channel of influenza A viruses (but not influenza B viruses), and the neuraminidase inhibitors (NAIs), which act by binding to the enzymatic site of the influenza neuraminidase (NA) thereby preventing progeny virions from being released from the host cell during viral replication. Antiviral resistance can occur in influenza viruses and render the drug ineffective for the treatment of patients. Virtually all influenza A viruses currently circulating in the human population are resistant to the adamantanes, while in comparison these viruses remain susceptible to the NAIs. In particular, very low NAI resistance has been observed in pandemic A(H1N1) 2009 viruses, even though unprecedented amounts of these drugs were used. 
